At­se­na pri­or­i­tizes reti­nal gene ther­a­py pipeline, trims staff as ex­ist­ing in­vestors re­fu­el the biotech 

At­se­na Ther­a­peu­tics has re­duced its staff, is look­ing for a part­ner and has reeled in more cash from ex­ist­ing in­vestors, the gene ther­a­py biotech told End­points News.

The North Car­oli­na start­up an­tic­i­pates 12-month re­sults from its first Phase I/II clin­i­cal tri­al by year’s end and be­gan a sep­a­rate Phase I/II study of its sec­ond gene ther­a­py in Au­gust, but has re­cent­ly laid off em­ploy­ees to con­serve cash, which in­cludes a re­cent in­sid­er-led Se­ries B, the com­pa­ny said, with about $24.5 mil­lion of $32 mil­lion raised so far, per an SEC fil­ing. CEO Patrick Ritschel de­clined to dis­close the size of the work­force re­duc­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER